Literature DB >> 33309909

Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy.

Chaitanya Divgi1, Jorge A Carrasquillo2, Ruby Meredith3, Youngho Seo4, Eric C Frey5, Wesley E Bolch6, Brian E Zimmerman7, Gamal Akabani8, Daniel A Jacobson9, Ben Brown10, Sandra M Davern9, Robert F Hobbs11, John Humm12, Eduardo G Moros13, David Morse14, Rao Papineni15, Pat Zanzonico12, Stanley H Benedict16, George Sgouros17.   

Abstract

Radiopharmaceutical therapy (RPT) continues to demonstrate tremendous potential in improving the therapeutic gains in radiation therapy by specifically delivering radiation to tumors that can be well assessed in terms of dosimetry and imaging. Dosimetry in external beam radiation therapy is standard practice. This is not the case, however, in RPT. This NRG (acronym formed from the first letter of the 3 original groups: National Surgical Adjuvant Breast and Bowel Project, the Radiation Therapy Oncology Group, and the Gynecologic Oncology Group)-National Cancer Institute Working Group review describes some of the challenges to improving RPT. The main priorities for advancing the field include (1) developing and adopting best practice guidelines for incorporating patient-specific dosimetry for RPT that can be used at both large clinics with substantial resources and more modest clinics that have limited resources, (2) establishing and improving strategies for introducing new radiopharmaceuticals for clinical investigation, (3) developing approaches to address the radiophobia that is associated with the administration of radioactivity for cancer therapy, and (4) solving the financial and logistical issues of expertise and training in the developing field of RPT.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33309909     DOI: 10.1016/j.ijrobp.2020.12.002

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

1.  Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy.

Authors:  Emilie Roncali; Jacek Capala; Stanley H Benedict; Gamal Akabani; Bryan Bednarz; Vikram Bhadrasain; Wesley E Bolch; Jeffrey C Buchsbaum; Norman C Coleman; Yuni K Dewaraja; Eric Frey; Michael Ghaly; Joseph Grudzinski; Robert F Hobbs; Roger W Howell; John L Humm; Charles A Kunos; Steve Larson; Frank I Lin; Mark Madsen; Saed Mirzadeh; David Morse; Daniel Pryma; George Sgouros; Sara St James; Richard L Wahl; Ying Xiao; Pat Zanzonico; Katherine Zukotynski
Journal:  J Nucl Med       Date:  2020-12-04       Impact factor: 10.057

Review 2.  Perspectives on metals-based radioimmunotherapy (RIT): moving forward.

Authors:  Jordan M White; Freddy E Escorcia; Nerissa T Viola
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

3.  Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma.

Authors:  Meghan M Bell; Nicholas T Gutsche; A Paden King; Kwamena E Baidoo; Olivia J Kelada; Peter L Choyke; Freddy E Escorcia
Journal:  Molecules       Date:  2020-12-22       Impact factor: 4.411

4.  Unsealed Source: Scope of Practice for Radiopharmaceuticals Among United States Radiation Oncologists.

Authors:  Utkarsh Shukla; Imran H Chowdhury; Jason M Beckta; Jacob S Witt; Matthew McFarlane; Chelsea J Miller; Kathryn E Huber; Matthew S Katz; Trevor J Royce; Mudit Chowdhary
Journal:  Adv Radiat Oncol       Date:  2021-10-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.